Swine flu windfall
Though a worrisome flu season is knocking at the Northern Hemisphere's door, the five biopharmaceutical companies awarded massive contracts by the US Department of Health and Human Services (HHS) for development and production of more than 195 million doses of swine flu vaccine can't really complain. The companies -- Novartis, GlaxoSmithKline, MedImmune, Australian drug maker CSL, and Sanofi-Pasteur -- have been hard at work developing and testing vaccines since the H1N1 surfaced in the US, Mex
Written byBob Grant
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
**__Related stories:__***linkurl:Journals speed up flu studies;https://www.the-scientist.com/blog/display/55686/
[11th May 2009]*linkurl:New HHS head takes on swine flu;https://www.the-scientist.com/blog/display/55668/
[29th April 2009]*linkurl:Can biotech tackle swine flu?;https://www.the-scientist.com/blog/display/55666/
[27th April 2009]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Meet the Author
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.
View Full Profile
